Canada: Health Canada Releases Revised Guidance Document On Approval Pathway For Biosimilars (Formerly "Subsequent-Entry Biologics")

Last Updated: January 12 2017
Article by Christopher Guerreiro, Marie-Helene Rochon and Nisha Anand

Most Read Contributor in Canada, December 2017


Health Canada has revised its guidance document on the approval pathway for biosimilar biologic drugs (biosimilars). The headline change is in the name: Health Canada has retired the "subsequent-entry biologics" moniker. The revised Biosimilars Guidance Document also contains overhauled guidelines for selecting reference biologics, satisfying the scientific review requirements of the Biologics and Genetic Therapies Directorate (BGTD), labelling, and post-market considerations.

The Biosimilars Guidance Document replaces the March 2010 Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) as Health Canada's primary resource on approval of biosimilars. Several of the changes were previewed in a draft revision that was published for consultation and comments in December 2015. Others were introduced in the revised guidance document following these consultations, which were completed in February 2016.


The Biosimilars Guidance Document continues Health Canada's policy of sui generis regulatory treatment for biosimilars. A biosimilar is not a "generic" biologic drug and unlike a generic pharmaceutical, cannot be approved by way of an abbreviated new drug submission. Instead, sponsors seeking approval for a biosimilar must file a new drug submission (NDS) and comply with the requirements in the Biosimilars Guidance Document.

The NDS pathway for biosimilars differs from that for pharmaceuticals because it can be completed with a reduced clinical and non-clinical package based upon demonstrated similarity to a previously approved biologic drug (but not another biosimilar). Although this is similar in principle to the comparisons made for generic drugs, authorization of a biosimilar is not a declaration of pharmaceutical equivalence, bioequivalence, or clinical equivalence to the reference biologic drug.

Biosimilars are regulated as new drugs and are subject to the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as well as the data-protection provisions in section C.08.004.1 of the Food and Drug Regulations.


The revised Biosimilars Guidance Document clarifies a number of existing processes and requirements. It also introduces changes intended to streamline the preparation and review of biosimilar submissions. Here are the highlights:

  • New options for reference biologic drugs. As before, a biosimilar must clearly identify and be subsequent to a biologic drug authorized in Canada. While it remains preferable that the same reference biologic drug is used throughout development of the biosimilar, the Biosimilars Guidance Document now permits the use of multiple reference biologic drugs under some circumstances. It also provides simplified requirements for supporting the selection of non-Canadian reference biologic drugs.
  • "Similar," not "comparable." In most cases, biosimilars are no longer described as being "comparable" to the reference biologic drug; instead, they are referred to as being "similar."
  • Clarified basis for determination of similarity. The Biosimilars Guidance Document clarifies that as a matter of policy, all relevant data will be taken into account when making a final determination of similarity. It also adjusts the emphasis of the data required to demonstrate similarity, providing that "...the weight of evidence should be provided by the structural and functional studies. The degree of similarity at the quality level will determine the scope and the breadth of the required non-clinical and clinical data. The non-clinical and clinical programmes should be designed to complement the structural and functional studies and address potential areas of residual uncertainty."
  • Broader acceptance of alternative means of manufacture. Biosimilars employing clearly different approaches to manufacture than the reference biologic drug may be eligible for approval under the Biosimilars Guidance Document. This is a departure from the previous policy that such products may not be suitable for authorization as biosimilars. In these cases, sponsors are cautioned to carefully consider expression-system differences that may present challenges to demonstrating similarity to the reference biologic drug.
  • Changes to information requirements for clinical trial applications (CTAs). In vivo animal studies may no longer be necessary to support a clinical trial application, provided the comparative structural, functional and non-clinical in vitro studies are considered satisfactory and no issues are identified that would preclude administration into humans. Sponsors are encouraged to request both scientific advice meetings (SAMs, discussed below) and pre-CTA consultation meetings to ensure compliance with BGTD requirements.
  • Changes to the non-clinical and clinical information required.
    • Non-clinical studies. The requirements for in vivo non-clinical studies have been simplified and reduced. These studies may not be necessary where similarity is well-established by structural and functional studies, and where extensive in vitro mechanistic studies are indicative of similarity. The former list of recommended studies has been deleted from this section; sponsors are encouraged to provide a scientific justification for their approach and consult with the BGTD.
    • Clinical studies. A preamble has been added to the section on clinical studies clarifying the purpose of the clinical programme: to show that there are no clinically meaningful differences between the biosimilar and the reference biologic drug. This is followed by detailed revisions to the guidelines for pharmacokinetic, pharmacodynamic, and clinical efficacy trials, the latter of which may not be required in all circumstances. These revisions are complemented by a new section outlining the requirements for comparative immunogenicity studies. The Biosimilars Guidance Document also clarifies that if clinical studies reveal differences between the biosimilar and the reference biologic drug, including statistical superiority of the biosimilar, it may be ineligible to proceed as a biosimilar.
  • More flexibility on indications. The Biosimilars Guidance Document now contains a clear policy statement that a biosimilar sponsor is eligible to apply for the indication(s) and condition(s) of use that are held by the reference biologic drug authorized in Canada. Clinical studies are not required to support approval in each indication, provided similarity has been established and a detailed scientific justification has been provided. A sponsor may also seek approval for indications beyond those for which the reference biologic drug is authorized, but these situations are outside the scope of the Biosimilars Guidance Document.
  • Revised labelling requirements. The product monograph guidelines have been amended to include additional detail regarding the comparisons and basis upon which the biosimilar was approved. In addition, the biosimilar product monograph should now include safety and efficacy information from the product monograph of the reference biologic drug.
  • Risk-management plans. Additional guidance is provided regarding the considerations that should be addressed in a risk-management plan, as well as a new reference to Health Canada's Guidance Document — Submission of Risk Management Plans and Follow-up Commitments.
  • Post-market requirements. The section in post-market requirements has been restructured. The sections on adverse drug reaction reporting and periodic safety update reports have been consolidated and the section on suspension or revocation of NOCs has been removed. A new section on post-NOC changes has also been added. This section reinforces that biosimilars are subject to the same regulatory requirements as other new drugs, including compliance with Health Canada's guidance documents on post-NOC changes. This section also recognises that Health Canada will consider supplemental new drug submissions seeking post-NOC approval for new indications held by the reference biologic drug on a case-by-case basis.
  • Consultation & SAM pilot programme. Sponsors are encouraged to consult with the BGTD early and throughout the approval process. Sponsors are also invited to participate in the three-year pilot of a "stepwise" review approach that was introduced in September 2015. Under the pilot programme, a sponsor provides the BGTD with the data it will rely upon to demonstrate similarity between a biosimilar and its reference biologic drug early in the development process. The BGTD will hold a SAM with the sponsor and, following that meeting, issue one of three recommendations:
    • to continue as a biosimilar;
    • to continue as a conventional drug; or
    • to provide additional comparability data, following which a recommendation will be made either to continue as a biosimilar or to further consult with the BGTD.

Fact Sheet

Health Canada has also revised its fact sheet on biosimilars.

In line with recent changes to the Guidance Document, the Fact Sheet has been substantially rewritten and contains an overview and description of the regulatory framework for biosimilars. The Fact Sheet also includes a new section on drug and patient access, which includes the following:

Health Canada's authorization of a biosimilar is independent of provincial, territorial, or private drug plan decisions regarding its formulary listing and reimbursement.

Health Canada's authorization of a biosimilar is not a declaration of equivalence between the biosimilar and its reference biologic drug, and is independent of any decision as to interchangeability between these drugs. Interchangeability decisions are a matter of provincial and territorial jurisdiction.

Health Canada recommends that decisions regarding switching to a biosimilar from its reference biologic drug should be made by treating physicians in consultation with the patient.


Original Norton Rose Fulbright Canada LLP publication:

Norton Rose Fulbright Canada LLP follow-up publication in Pharma in brief regarding the Fact Sheet:

Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs (November 14, 2016)

Previous documents: Guidance For Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) (March 5, 2010); Draft – Revised Guidance Document: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) (December 7, 2015)

Pilot programme: Notice – Subsequent Entry Biologics Scientific Advice Meeting Pilot

Related enactments: Food and Drugs Act, RSC 1985, c F-27; Food and Drug Regulations, CRC, c 870

About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions